ProCE Banner Activity

Novel, Next-Generation HIV-1 Maturation Inhibitor GSK3640254 Demonstrates Dose-Dependent Antiviral Response in Treatment-Naive Patients With HIV Infection

Slideset Download
Conference Coverage
Phase IIa study demonstrates that novel maturation inhibitor exhibits dose-response antiviral activity, in vivo concentrations above clinical efficacy targets, and good tolerability.

Released: March 10, 2021

Expiration: March 09, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead

Janssen Therapeutics Division of Janssen Products

Merck Sharp & Dohme Corp.

ViiV Healthcare